Abstract
The Worldwide Innovative Networking (WIN) Symposium is the annual gathering of WIN consortium members from across the globe, representing academic institutions, pharmaceutical partners, technology companies and charitable organisations, to discuss ongoing research and the latest developments in precision oncology. The symposium held in Paris, France on 25–26 June was structured into five plenary sessions, two open forums and poster presentations.This year marked the 10th anniversary of the consortium, and the programme anchored itself with retrospectives of recent breakthroughs in personalised medicine, programme sessions reviewing the iterative design of trials in precision oncology at present, and the future of implementing personalised medicine initiatives in US and EU healthcare systems for the maximum patient benefit.This year was also marked by the absence of Dr John Mendelsohn, who has stepped down as chairman, and co-founder Professor Tomas Tursz, who passed away in April this year. The latter was given a brief memorial session at the conclusion of the symposium.
Highlights
In addressing an audience question of when and how underlying genomic changes can manifest as a primary lesion, Professor Esserman highlighted that the effect of hormone therapy on response biomarkers can point to patients in the low/ultra-low risk categories she described earlier, and spare them from unnecessary treatment
Razelle Kurzrock, (UC San Diego Moores Cancer Center, San Diego, USA), chair of the Clinical Trials Committee, took to the podium for a more in-depth discussion of the WINTHER trial starting with patient stratification; patients who had their normal organ tissue and tumour tissue RNA assayed through Agilent dual colour screening had their treatment selected based on WINTHER algorithm indications for the best transcriptome-based therapy, or if next-generation sequencing did not pick up an actionable mutation to inform DNA-led therapy selection
Professor Hahn concluded his session with a look at the ‘Dream List’ of personalised oncology, similar to that discussed by John Mendelsohn previously) [3], and how the goals of integrating Big Data and biomarkers beyond genomics are becoming realised elements of care, through Worldwide Innovative Networking (WIN) initiatives such as the WINTHER and SPRING trials
Summary
In addressing an audience question of when and how underlying genomic changes can manifest as a primary lesion, Professor Esserman highlighted that the effect of hormone therapy on response biomarkers can point to patients in the low/ultra-low risk categories she described earlier, and spare them from unnecessary treatment. Another question on treating small primary lesions numbering only a few hundred cells with matched therapy was fielded first by Dr Hood, stating that the data gathered from many patients whose disease is managed as an N of 1 study will eventually indicate when to act in other patients, and which biomarkers of progression to be aware of Professor Esserman challenged that constant population screening was an expense beyond consideration, but that stratifying high-risk groups could do more to inform disease development and screening process, and that the lowest 15%–20% risk patients could continue without screening or revisiting.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
